ClinicalTrials.Veeva

Menu
The trial is taking place at:
S

Saint Louis University | SLUCare Academic Pavilion - Endocrinology Division Research

Veeva-enabled site

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

CymaBay Therapeutics logo

CymaBay Therapeutics

Status and phase

Enrolling
Phase 3

Conditions

Primary Biliary Cirrhosis

Treatments

Drug: Seladelpar 5 mg Capsule
Drug: Seladelpar 10 mg Capsule

Study type

Interventional

Funder types

Industry

Identifiers

NCT03301506
CB8025-31731-RE

Details and patient eligibility

About

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Full description

Primary:

To evaluate the long-term safety and tolerability of seladelpar

Secondary:

  • To evaluate the long-term efficacy of seladelpar
  • To evaluate the effect of seladelpar on patient-reported outcomes (pruritus)

Enrollment

500 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Must have given written informed consent (signed and dated)
  2. Participated in a PBC study with seladelpar
  3. Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion criteria

Exclusion criteria are only applicable for subjects with a seladelpar interruption greater than 4 weeks prior to Day 1 of this study and for subjects who participated in CB8025-21838 irrespective of seladelpar interruption.

  1. Treatment-related adverse event (AE) leading to seladelpar discontinuation in a previous PBC study with seladelpar (MBX-8025)

  2. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer)

  3. AST or ALT above 3 × the upper limit of normal (ULN)

  4. Total bilirubin above 2 × ULN

  5. MELD score ≥ 12. For subjects on anticoagulation medication, evaluation of the baseline INR, in concert with any current dose adjustments in anti-coagulant medications, will be taken into account when calculating this score. This will be done in consultation with the medical monitor.

  6. Evidence of advanced PBC as defined by the Rotterdam criteria: albumin below 1× the lower limit of normal (LLN) AND total bilirubin above 1 × ULN)

  7. eGFR ≤45 mL/min/1.73 m2 (calculated by MDRD formula)

  8. Auto-immune hepatitis

  9. Primary sclerosing cholangitis

  10. Known history of alpha-1-antitrypsin deficiency

  11. Known history of chronic viral hepatitis

  12. For females, pregnancy or breast-feeding

  13. Use of colchicine, methotrexate, azathioprine, or long-term use of systemic steroids (e.g. prednisone, prednisolone, budesonide) (>2 weeks) within 2 months prior to Screening

  14. Current use of fibrates or use of fibrates within 3 months prior to Screening

  15. Current use of obeticholic acid or use of obeticholic acid within 3 months prior to Screening

  16. Use of an experimental or unapproved treatment for PBC within 3 months prior to Screening

  17. History of malignancy diagnosed or treated, actively or within 2 years, or active evaluation for malignancy; localized treatment of squamous or non-invasive basal cell skin cancers and cervical carcinoma in-situ is allowed if appropriately treated prior to Screening

  18. Treatment with any other investigational therapy or medical device within 30 days or within 5 half-lives, whatever is longer, prior to Screening

  19. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator

  20. Immunosuppressant therapies (e.g., cyclosporine, tacrolimus, anti-TNF or other immunosuppressive biologics)

  21. Other medications that effect liver or GI functions such as absorption of medications or the roux-en-y gastric bypass procedure may be prohibited and should be discussed with the medical monitor on a case-by-case basis

  22. Positive for:

    1. Hepatitis B, defined as the presence of hepatitis B surface antigen
    2. Hepatitis C, defined as the presence of hepatitis C virus ribonucleic acid (RNA)
    3. Human immunodeficiency virus (HIV) antibody
  23. Active COVID-19 infection during screening

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

500 participants in 2 patient groups

Seladelpar 5 mg Capsules
Experimental group
Treatment:
Drug: Seladelpar 5 mg Capsule
Seladelpar 10 mg Capsule
Experimental group
Treatment:
Drug: Seladelpar 10 mg Capsule

Trial contacts and locations

118

Loading...

Central trial contact

Barry Crittenden, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems